EA036942B1 - Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза - Google Patents

Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза Download PDF

Info

Publication number
EA036942B1
EA036942B1 EA201690980A EA201690980A EA036942B1 EA 036942 B1 EA036942 B1 EA 036942B1 EA 201690980 A EA201690980 A EA 201690980A EA 201690980 A EA201690980 A EA 201690980A EA 036942 B1 EA036942 B1 EA 036942B1
Authority
EA
Eurasian Patent Office
Prior art keywords
chlorophenyl
compound
compounds
treatment
present
Prior art date
Application number
EA201690980A
Other languages
English (en)
Russian (ru)
Other versions
EA201690980A1 (ru
Inventor
Шон Кэнпил
Джуд Кэнон
Пол Хьюз
Джонатан Д. Олинер
Ричард Дж. Риклес
Анн Й. Саики
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA201690980A1 publication Critical patent/EA201690980A1/ru
Publication of EA036942B1 publication Critical patent/EA036942B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EA201690980A 2013-11-11 2014-11-11 Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза EA036942B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361902717P 2013-11-11 2013-11-11
PCT/US2014/065034 WO2015070224A2 (en) 2013-11-11 2014-11-11 Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Publications (2)

Publication Number Publication Date
EA201690980A1 EA201690980A1 (ru) 2016-09-30
EA036942B1 true EA036942B1 (ru) 2021-01-18

Family

ID=52001089

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201690980A EA036942B1 (ru) 2013-11-11 2014-11-11 Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза
EA202092456A EA202092456A3 (ru) 2013-11-11 2014-11-11 Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202092456A EA202092456A3 (ru) 2013-11-11 2014-11-11 Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака

Country Status (33)

Country Link
US (3) US20160287569A1 (cg-RX-API-DMAC7.html)
EP (2) EP3068393B9 (cg-RX-API-DMAC7.html)
JP (5) JP2016535795A (cg-RX-API-DMAC7.html)
KR (3) KR102305351B1 (cg-RX-API-DMAC7.html)
CN (2) CN105934255A (cg-RX-API-DMAC7.html)
AP (1) AP2016009243A0 (cg-RX-API-DMAC7.html)
AU (3) AU2014346354A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016010564A2 (cg-RX-API-DMAC7.html)
CA (1) CA2930244A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016001131A1 (cg-RX-API-DMAC7.html)
CY (1) CY1125358T1 (cg-RX-API-DMAC7.html)
DK (1) DK3068393T5 (cg-RX-API-DMAC7.html)
EA (2) EA036942B1 (cg-RX-API-DMAC7.html)
ES (1) ES2916721T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220718T1 (cg-RX-API-DMAC7.html)
HU (1) HUE059351T2 (cg-RX-API-DMAC7.html)
IL (2) IL245568B (cg-RX-API-DMAC7.html)
LT (1) LT3068393T (cg-RX-API-DMAC7.html)
MA (1) MA39094B1 (cg-RX-API-DMAC7.html)
MX (6) MX391859B (cg-RX-API-DMAC7.html)
MY (1) MY192088A (cg-RX-API-DMAC7.html)
NZ (2) NZ720766A (cg-RX-API-DMAC7.html)
PH (1) PH12016500871A1 (cg-RX-API-DMAC7.html)
PL (1) PL3068393T3 (cg-RX-API-DMAC7.html)
PT (1) PT3068393T (cg-RX-API-DMAC7.html)
RS (1) RS63348B9 (cg-RX-API-DMAC7.html)
SG (1) SG10201902429PA (cg-RX-API-DMAC7.html)
SI (1) SI3068393T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200241T1 (cg-RX-API-DMAC7.html)
TN (1) TN2016000176A1 (cg-RX-API-DMAC7.html)
UA (1) UA120750C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015070224A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201603342B (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
WO2012021875A1 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with triazole linkers
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物
DK3068393T5 (da) * 2013-11-11 2022-08-22 Amgen Inc Kombinationsterapi som inkluderer en mdm2-inhibitor og et eller flere yderligere farmaceutisk aktive midler til behandlingen af kræftformer
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
KR102595395B1 (ko) 2015-02-20 2023-10-27 다이이찌 산쿄 가부시키가이샤 암의 병용 치료법
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2017037586A1 (en) * 2015-08-28 2017-03-09 Novartis Ag Combination therapy using pi3k inhbitor and mdm2 inhibitor
AU2016314082B2 (en) * 2015-08-28 2019-07-25 Novartis Ag Mdm2 inhibitors and combinations thereof
WO2017200826A1 (en) * 2016-05-16 2017-11-23 Albert Einstein College Of Medicine, Inc. Assays and compounds for treatment of cancer
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
WO2018074387A1 (ja) * 2016-10-17 2018-04-26 第一三共株式会社 Ｍｄｍ２阻害剤とｄｎａメチルトランスフェラーゼ阻害剤との併用治療法
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
IL308399B2 (en) * 2018-04-30 2025-08-01 Kartos Therapeutics Inc Methods of treating cancer
EP3801476A4 (en) * 2018-05-25 2022-07-06 Kartos Therapeutics, Inc. METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN110963958B (zh) * 2018-09-30 2025-10-10 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
TW202034918A (zh) * 2018-12-11 2020-10-01 美商卡托斯醫療公司 治療眼睛病況之方法及組合物
CN111434353A (zh) * 2019-02-02 2020-07-21 中国科学院上海营养与健康研究所 Ras抑制剂筛选及疗效标志物
WO2021018032A1 (en) * 2019-07-26 2021-02-04 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
CN113801120B (zh) * 2020-06-15 2024-03-22 苏州亚盛药业有限公司 Mdm2抑制剂的微悬浮液以及治疗应用
AR123227A1 (es) * 2020-08-12 2022-11-09 Servier Pharmaceuticals Llc Terapias combinadas para su uso en el tratamiento del cáncer
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN115089585A (zh) * 2022-08-05 2022-09-23 中国科学院大学宁波华美医院 Mdm2抑制剂rg7112联合依托泊苷在治疗肺癌中的应用
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
WO2024254156A1 (en) * 2023-06-05 2024-12-12 Kartos Therapeutics, Inc. Treatment of endometrial cancer with mdm2 inhibitors
WO2025098488A1 (zh) * 2023-11-09 2025-05-15 深圳艾欣达伟医药科技有限公司 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110319378A1 (en) * 2010-06-04 2011-12-29 Amgen Inc. Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
US20130245039A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU2503A (sh) 2000-07-19 2006-05-25 Warner-Lambert Company Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina
CN101389335A (zh) 2004-10-18 2009-03-18 安姆根有限公司 噻二唑化合物和使用方法
CN101421265A (zh) 2006-01-18 2009-04-29 安姆根有限公司 作为蛋白激酶b(pkb)抑制剂的噻唑化合物
AU2008231384B2 (en) 2007-03-23 2011-09-15 Amgen Inc. Heterocyclic compounds and their use
PL2139882T3 (pl) 2007-03-23 2014-05-30 Amgen Inc 3-podstawione pochodne chinoliny lub chinoksaliny i ich zastosowanie jako inhibitorów 3-kinazy fosfatydyloinozytolu (pi3k)
PT2137186E (pt) 2007-03-23 2016-03-30 Amgen Inc Compostos heterocíclicos e suas utilizações
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
EP2170887A2 (en) 2007-06-07 2010-04-07 Amgen Inc. Heterocyclic compounds as raf kinase modulators
CA2693473A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
WO2009017822A2 (en) 2007-08-02 2009-02-05 Amgen Inc. Pi3 kinase modulators and methods of use
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
EP2231656A1 (en) 2007-12-19 2010-09-29 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
ATE531372T1 (de) 2008-04-07 2011-11-15 Amgen Inc Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
WO2009155121A2 (en) 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
WO2010083246A1 (en) 2009-01-15 2010-07-22 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
CA2752527C (en) 2009-02-18 2014-09-23 Amgen Inc. Indole/benzimidazole compounds as mtor kinase inhibitors
AU2010226490A1 (en) 2009-03-20 2011-10-06 Amgen Inc. Inhibitors of PI3 kinase
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
WO2010132598A1 (en) 2009-05-13 2010-11-18 Amgen Inc. Heteroaryl compounds as pikk inhibitors
AU2010266064A1 (en) 2009-06-25 2012-01-19 Amgen Inc. 4H - pyrido [1, 2 - a] pyrimidin - 4 - one derivatives as PI3 K inhibitors
MX2011013666A (es) 2009-06-25 2012-03-06 Amgen Inc Compuestos heterociclicos y sus usos.
JP2012531436A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用
AR077267A1 (es) 2009-06-25 2011-08-17 Amgen Inc Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
ES2528485T3 (es) 2009-09-11 2015-02-10 Amgen, Inc N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina para su uso en el tratamiento del cáncer resistente a agentes antimitóticos
KR20120031734A (ko) * 2010-09-27 2012-04-04 삼성전자주식회사 급성 골수성 백혈병 환자의 시타라빈 민감성을 예측하기 위한 키트 및 방법
EP2670396A1 (en) * 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
JP2015511632A (ja) 2012-03-30 2015-04-20 武田薬品工業株式会社 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与
AU2014219075C1 (en) 2013-02-19 2018-09-06 Amgen Inc. Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
EP2961735B1 (en) 2013-02-28 2017-09-27 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物
JOP20200296A1 (ar) * 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
CA2919294A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Volasertib in combination with decitabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii
DK3068393T5 (da) * 2013-11-11 2022-08-22 Amgen Inc Kombinationsterapi som inkluderer en mdm2-inhibitor og et eller flere yderligere farmaceutisk aktive midler til behandlingen af kræftformer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110319378A1 (en) * 2010-06-04 2011-12-29 Amgen Inc. Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
US20130245039A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
BOSE P, GRANT S: "Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML)", LEUKEMIA RESEARCH REPORTS, ELSEVIER LTD., GB, vol. 2, no. 1, 1 January 2013 (2013-01-01), GB, pages 12 - 14, XP002740451, ISSN: 2213-0489, DOI: 10.1016/j.lrr.2012.11.006 *
CHITHRA D. PALANI; JAMES F. BECK; JÜRGEN SONNEMANN: "Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression", INVESTIGATIONAL NEW DRUGS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 30, no. 1, 3 August 2010 (2010-08-03), Bo, pages 25 - 36, XP035000732, ISSN: 1573-0646, DOI: 10.1007/s10637-010-9510-7 *
FALCHOOK G S, LEWIS K D, INFANTE J R, GORDON M S, VOGELZANG N J, DEMARINI D J, SUN P, MOY C, SZABO S A, ROADCAP L T, PEDDAREDDIGAR: "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 13, no. 8, 1 August 2012 (2012-08-01), AMSTERDAM, NL, pages 782 - 789, XP002727794, ISSN: 1470-2045, DOI: 10.1016/S1470-2045(12)70269-3 *
FENG J, TAMASKOVIC R, YANG Z, BRAZIL D P, MERLO A, HESS D, HEMMINGS B A: "Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 279, no. 34, 20 August 2004 (2004-08-20), pages 35510 - 35517, XP002740653, ISSN: 0021-9258, DOI: 10.1074/jbc.M404936200 *
FLAHERTY KEITH T, ET AL: "Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations", THE NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 367, no. 18, 1 November 2012 (2012-11-01), US, pages 1694 - 1703, XP002725869, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1210093 *
GILES FRANCIS; CORTES JORGE; BERGSTROM DONALD A; XIAO ALAN; BRISTOW PENNY; JONES DAN; VERSTOVSEK SRDAN; THOMAS DEBORAH; KANTARJIAN: "MK-0457, a novel aurora kinase and BCR-ABL inhibitor, is active against BCR-ABL T315I mutant chronic myelogenous leukemia (CML)", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 11, Part 1, 1 November 2006 (2006-11-01), US, pages 52a, XP009124755, ISSN: 0006-4971 *
J. G. GREGER, S. D. EASTMAN, V. ZHANG, M. R. BLEAM, A. M. HUGHES, K. N. SMITHEMAN, S. H. DICKERSON, S. G. LAQUERRE, L. LIU, T. M. : "Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC., vol. 11, no. 4, 1 April 2012 (2012-04-01), pages 909 - 920, XP055057160, ISSN: 15357163, DOI: 10.1158/1535-7163.MCT-11-0989 *
J. M. GOZGIT, WONG M. J., WARDWELL S., TYNER J. W., LORIAUX M. M., MOHEMMAD Q. K., NARASIMHAN N. I., SHAKESPEARE W. C., WANG F., D: "Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC., vol. 10, no. 6, 1 June 2011 (2011-06-01), pages 1028 - 1035, XP055056925, ISSN: 15357163, DOI: 10.1158/1535-7163.MCT-10-1044 *
JI Z, KUMAR R, TAYLOR M, RAJADURAI A, MARZUKA-ALCALÁ A, CHEN Y E, NJAUW C N, FLAHERTY K, JÖNSSON G, TSAO H.: "Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 19, no. 16, 15 August 2013 (2013-08-15), US, pages 4383 - 4391, XP002734225, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-13-0074 *
JI Z, NJAUW C N, TAYLOR M, NEEL V, FLAHERTY K T, TSAO H: "p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NATURE PUBLISHING GROUP, US, vol. 132, no. 2, 1 February 2012 (2012-02-01), US, pages 356 - 364, XP002694638, ISSN: 1523-1747, DOI: 10.1038/jid.2011.313. *
KAO C L, HSU H S, CHEN H W, CHENG T H: "Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells.", CANCER LETTERS, NEW YORK, NY, US, vol. 286, no. 2, 28 December 2009 (2009-12-28), US, pages 250 - 259, XP002740446, ISSN: 0304-3835, DOI: 10.1016/j.canlet.2009.05.031 *
KENSUKE KOJIMA, KONOPLEVA MARINA, MCQUEEN TERESA, BRIEN SUSAN O ', PLUNKETT WILLIAM, ANDREEFF MICHAEL: "Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription- dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia", BLOOD, vol. 108, no. 3, 1 August 2006 (2006-08-01), pages 993 - 1000, XP055140017, DOI: 10.1182/blood-2005-12-5148 *
KHOURY H J, CORTES J E, KANTARJIAN H M, GAMBACORTI-PASSERINI C, BACCARANI M, KIM D W, ZARITSKEY A, COUNTOURIOTIS A, BESSON N, LEIP: "Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY NLD, US, vol. 119, no. 15, 12 April 2012 (2012-04-12), US, pages 3403 - 3412, XP002740449, ISSN: 1528-0020, DOI: 10.1182/blood-2011-11-390120 *
KOJIMA K, KONOPLEVA M, SAMUDIO I J, RUVOLO V, ANDREEFF M.: "Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 67, no. 7, 1 April 2007 (2007-04-01), US, pages 3210 - 3219, XP002740444, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-2712 *
KOJIMA K, KONOPLEVA M, SAMUDIO I J, SCHOBER W D, BORNMANN W G, ANDREEFF M.: "Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.", CELL CYCLE, LANDES BIOSCIENCE, US, vol. 5, no. 23, 1 December 2006 (2006-12-01), US, pages 2778 - 2786, XP002740450, ISSN: 1551-4005, DOI: 10.4161/cc.5.23.3520 *
LIU D, XING M.: "Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.", THYROID., MARY ANN LIEBERT, NEW YORK, NY., US, vol. 18, no. 8, 1 August 2008 (2008-08-01), US, pages 853 - 864, XP002740459, ISSN: 1050-7256, DOI: 10.1089/thy.2007.0357 *
LONG J, PARKIN B, OUILLETTE P, BIXBY D, SHEDDEN K, ERBA H, WANG S, MALEK S N: "Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY NLD, US, vol. 116, no. 1, 8 July 2010 (2010-07-08), US, pages 71 - 80, XP002740447, ISSN: 1528-0020, DOI: 10.1182/blood-2010-01-261628 *
LU WENGE ET AL: "Activation of p53 by roscovitine-mediated suppression of MDM2 expression", ONCOGENE, NATURE PUBLISHING GROUP UK, LONDON, vol. 20, no. 25, 31 May 2001 (2001-05-31), London, pages 3206 - 3216, XP002292792, ISSN: 0950-9232, DOI: 10.1038/sj.onc.1204412 *
MARTINELLI E, TROIANI T, D'AIUTO E, MORGILLO F, VITAGLIANO D, CAPASSO A, COSTANTINO S, CIUFFREDA L P, MEROLLA F, VECCHIONE L, DE V: "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC., US, vol. 133, no. 9, 1 November 2013 (2013-11-01), US, pages 2089 - 2101, XP002740445, ISSN: 0020-7136, DOI: 10.1002/ijc.28236 *
NAGMA KHAN, MICHAEL JEFFERS, SAMPATH KUMAR, CRAIG HACKETT, FERENC BOLDOG, NICHOLAI KHRAMTSOV, XIAOZHONG QIAN, EVAN MILLS, STANNY�C: "Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors", BIOCHEMICAL JOURNAL, PUBLISHED BY PORTLAND PRESS ON BEHALF OF THE BIOCHEMICAL SOCIETY., vol. 409, no. 2, 15 January 2008 (2008-01-15), pages 581, XP055074060, ISSN: 02646021, DOI: 10.1042/BJ20070779 *
TIANJUN ZHOU, COMMODORE LOIS, HUANG WEI-SHENG, WANG YIHAN, THOMAS MATHEW, KEATS JEFF, XU QIHONG, RIVERA VICTOR M., SHAKESPEARE WIL: "Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance", CHEMICAL BIOLOGY & DRUG DESIGN, BLACKWELL MUNKSGAARD, vol. 77, no. 1, 1 January 2011 (2011-01-01), pages 1 - 11, XP055065379, ISSN: 17470277, DOI: 10.1111/j.1747-0285.2010.01054.x *
WANG, D. BOERNER, S.A. WINKLER, J.D. LORUSSO, P.M.: "Clinical experience of MEK inhibitors in cancer therapy", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., NL, vol. 1773, no. 8, 1 August 2007 (2007-08-01), NL, pages 1248 - 1255, XP022181677, ISSN: 0167-4889, DOI: 10.1016/j.bbamcr.2006.11.009 *
WEIGUO ZHANG, MARINA KONOPLEVA, JARED K. BURKS, KAREN C. DYWER, WENDY D. SCHOBER, JER-YEN YANG, TERESA J. MCQUEEN, MIEN-CHIE HU: "Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 70, no. 6, 15 March 2010 (2010-03-15), US, pages 2424 - 2434, XP002740443, ISSN: 1538-7445, DOI: 10.1158/0008-5472.CAN-09-0878 *
ZAULI G, VOLTAN R, BOSCO R, MELLONI E, MARMIROLI S, RIGOLIN G M, CUNEO A, SECCHIERO P.: "Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 17, no. 4, 15 February 2011 (2011-02-15), US, pages 762 - 770, XP002740448, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-2572 *

Also Published As

Publication number Publication date
KR102473485B1 (ko) 2022-12-01
MX391859B (es) 2025-03-12
PH12016500871A1 (en) 2016-07-04
SMT202200241T1 (it) 2022-09-14
AU2022201495A1 (en) 2022-03-24
CL2016001131A1 (es) 2017-04-17
AU2020201321B2 (en) 2022-03-10
CN112933236A (zh) 2021-06-11
LT3068393T (lt) 2022-08-10
CN105934255A (zh) 2016-09-07
MA39094B1 (fr) 2020-06-30
IL245568A0 (en) 2016-06-30
KR102305351B1 (ko) 2021-09-24
EA201690980A1 (ru) 2016-09-30
KR20220167335A (ko) 2022-12-20
WO2015070224A2 (en) 2015-05-14
MX2016006025A (es) 2016-12-02
JP2023033414A (ja) 2023-03-10
KR20210119550A (ko) 2021-10-05
MX2022012320A (es) 2022-10-27
SI3068393T1 (sl) 2022-11-30
HRP20220718T1 (hr) 2022-09-30
IL245568B (en) 2021-09-30
RS63348B9 (sr) 2022-10-31
NZ758548A (en) 2022-02-25
US10881648B2 (en) 2021-01-05
DK3068393T3 (da) 2022-06-13
BR112016010564A2 (pt) 2017-10-10
TN2016000176A1 (en) 2017-10-06
PL3068393T3 (pl) 2022-10-03
EP3068393A2 (en) 2016-09-21
MX2020001550A (es) 2022-04-26
AU2014346354A1 (en) 2016-05-26
RS63348B1 (sr) 2022-07-29
DK3068393T5 (da) 2022-08-22
CA2930244A1 (en) 2015-05-14
AP2016009243A0 (en) 2016-05-31
IL285646A (en) 2021-09-30
WO2015070224A3 (en) 2015-08-13
EA202092456A2 (ru) 2021-05-31
AU2020201321A1 (en) 2020-03-12
US20190290630A1 (en) 2019-09-26
EA202092456A3 (ru) 2021-09-30
MA39094A1 (fr) 2018-07-31
JP6972274B2 (ja) 2021-11-24
MX393610B (es) 2025-03-24
HUE059351T2 (hu) 2022-11-28
EP4039256A1 (en) 2022-08-10
JP2022009805A (ja) 2022-01-14
ZA201603342B (en) 2025-04-30
MX2022008175A (es) 2022-08-15
PT3068393T (pt) 2022-06-14
KR20160074012A (ko) 2016-06-27
NZ720766A (en) 2022-02-25
JP2019142916A (ja) 2019-08-29
JP2016535795A (ja) 2016-11-17
US20160287569A1 (en) 2016-10-06
MY192088A (en) 2022-07-26
JP2021004259A (ja) 2021-01-14
SG10201902429PA (en) 2019-04-29
CY1125358T1 (el) 2024-09-20
MX2020013670A (es) 2022-09-30
UA120750C2 (uk) 2020-02-10
EP3068393B1 (en) 2022-03-09
MX2019009853A (es) 2019-10-14
US20220280495A1 (en) 2022-09-08
MX378969B (es) 2025-03-11
ES2916721T3 (es) 2022-07-05
EP3068393B9 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
EA036942B1 (ru) Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза
EP2694485B1 (en) Combination of akt inhibitor compound and vemurafenib for use in therapeutic treatments
JP2023065588A (ja) Ｔｌｒ７／８アンタゴニストおよびそれらの使用
US12295939B2 (en) Substituted benzothiophene analogs as selective estrogen receptor degraders
JP2022544211A (ja) がんの治療における使用のための重水素化化合物
TW201028393A (en) Kinase inhibitors and methods of their use
KR20160018576A (ko) Mdm2 저해제의 결정형 및 그의 제조 방법
HK40078013A (en) Combination therapy including an mdm2 inhibitor and dasatinib or nilotinib for the treatment of chronic myeloid leukemia
EP4495111A1 (en) Novel compound and use thereof for inhibiting checkpoint kinase 2
HK40058270A (en) Pd-l1 antagonist compound
HK1228256B (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK1228256A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK1193753A (en) Combinations of akt inhibitor compounds and erlotinib, and methods of use